Bradia is generally used for managing conditions characterized by periods of heightened symptoms relevant in contexts involving heightened systemic burden. Its therapeutic application is centered on addressing symptoms related to heightened physiological activity to support general well-being during symptomatic phases.

The main therapeutic domains for this type of medication include the symptomatic treatment of chronic stable angina pectoris (symptoms related to physical discomfort that occur during physical exertion) and the treatment of chronic heart failure with systolic dysfunction. Both applications are relevant in clinical settings that involve acute or unstable symptom patterns where the patient has an elevated heart rate.

The medicine may assist with maintaining functional stability during these episodes. The medication supports general well-being during symptomatic phases, a benefit that is commonly expressed as:

“The medicine may help patients cope more steadily with symptom fluctuations and assists with maintaining functional stability.”

The medication contributes to easing the overall symptom load and helps improve day-to-day comfort during symptomatic periods.

Quick Fact: Relief for symptoms related to physical discomfort and symptoms that create noticeable physiological strain.

Regulatory References

1. European Medicines Agency (EMA) Summary of Product Characteristics

Eligibility for Bradia (Ivabradine)

Official regulatory guidelines define specific patient populations permitted or prohibited from using Bradia. Eligibility is determined by underlying physiological status, cardiac conditions, organ function, and reproductive status.

Bradia is approved for use in adult patients and pediatric patients aged 6 months to 18 years with heart failure. For initiation, patients must be in sinus rhythm with a resting heart rate of 70 beats per minute or higher, as per regulatory labeling for certain indications.

---

Contraindications (Must Not Use)

Population / Condition	Restriction Basis
Heart Rate	Resting rate below 60 or 70 bpm (depending on region)
Severe CV Conditions	Acute decompensated heart failure, cardiogenic shock, unstable angina
Conduction Defects	Sick sinus syndrome, 3rd degree AV block (unless demand pacemaker is present)
Organ Function	Severe hepatic impairment (Child-Pugh C)
Reproductive Status	Pregnancy, lactation, or women without reliable contraception
Drug Interactions	Concomitant use with strong CYP3A4 inhibitors or verapamil/diltiazem

---

Conditional Use

Use is not recommended or requires caution in patients with conditions like atrial fibrillation, 2nd degree AV block, or severe renal impairment (CrCl < 15 ml/min). For patients aged 75 years or more, a lower starting dose should be considered.

Interactions with other medicines and products

Bradia (Ivabradine) has an official interaction profile focused on its metabolism and its intended effect on heart rate, as documented in regulatory prescribing information. Interactions are primarily categorized as prohibitions or restrictions due to the risk of altering drug exposure or causing excessive heart rate reduction.

Documented Prohibitions and Restrictions

Category	Interaction Classification	Interacting Substances/Circumstances
Contraindicated Combinations	Formal Prohibitions	Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir); Heart Rate-Reducing Calcium Channel Blockers (Verapamil, Diltiazem); Pacemaker Dependence; Severe Hepatic Impairment.
Exposure Alteration	Substances to Avoid	Strong CYP3A4 Inducers (e.g., Rifampicin, St. John's wort); Grapefruit/Grapefruit Juice.
Pharmacodynamic Risk	Use with Caution	Other Negative Chronotropes (e.g., specific Beta-blockers, Digoxin); QT-Prolonging Medicinal Products.

Interaction-Related Requirements

Bradia is primarily metabolized by the CYP3A4 enzyme; therefore, co-administration with strong inhibitors is strictly prohibited as it leads to a severe increase in systemic exposure. Conversely, co-administration with strong inducers is avoided due to the potential for significant reduction in exposure. The co-administration of Ivabradine with Itraconazole is prohibited during treatment and for a period of two weeks after treatment completion. Regulatory information also specifies that the film-coated tablet should be taken with meals.

Selective Pacemaker Current Blockade

Ivabradine's mechanism involves specific inhibition of the If Current (Funny Current), which is carried by mathbfHCN channels in the Sinoatrial (SA) node. The drug acts as a selective blocker, reducing the influx of positive ions and slowing the spontaneous electrical signaling that regulates heart rate. This action occurs without major effect on myocardial contractility (inotropy) or vascular tone.

---

Mechanism of Heart Rate Reduction

The primary physiological consequence of If current inhibition is a reduction in the slope of diastolic depolarization, the electrical signal that builds up between heartbeats. This action prolongs the time required for the heart to initiate the next beat, resulting in a pure reduction in heart rate (negative chronotropy). The inhibitory effect is rate-dependent, becoming more pronounced when the If channels are more active.

---

Impact on Myocardial Oxygen Economy

The prolongation of the diastolic phase, or diastolic filling time, allows for increased blood flow and oxygen delivery to the heart muscle via the coronary arteries. By reducing the number of contractions per minute and extending this resting period, the drug mechanism simultaneously increases oxygen supply to the heart muscle and reduces its overall oxygen demand, leading to an altered balance between myocardial oxygen supply and demand.

Official Administration Guidelines for Bradia (Ivabradine)

Bradia (Ivabradine) is indicated for oral administration and is available as film-coated tablets (in 5 mg and 7.5 mg strengths) or as an oral solution. The 5 mg tablet is scored, allowing it to be divided to provide the 2.5 mg dose necessary for starting or maintenance regimens.

Dosing Schedule and Constraints

The medication must be taken twice daily (BID), once in the morning and once in the evening. A fundamental condition for proper use is that both tablets or the oral solution must be administered with meals to ensure consistent absorption. For most adults, the usual starting dose is 5 mg BID, with a maximum dose of 7.5 mg BID. For older adults (aged 75 years or more), a lower initial dose of 2.5 mg BID is typically considered before beginning the titration schedule.

Titration and Adjustment Protocol

The dosing is managed via a heart rate-dependent adjustment protocol. Increases or decreases in dose, within the 2.5 mg BID to 7.5 mg BID range, are performed at intervals of approximately two weeks. This adjustment is based on the patient's measured resting heart rate, ensuring the dose aligns with the intended physiological response. If a dose is missed, patients should not take a double dose; they must resume the routine with the next scheduled dose at the usual time. No adjustment is typically required for mild to moderate kidney or liver impairment.

Research evidence / Overview of Studies for Bradia

Evidence for use in Chronic Stable Angina Pectoris

Researchers have conducted large, controlled studies, including Randomized Controlled Trials (RCTs) and pooled analyses, to explore the use of Bradia for chronic stable angina, a condition characterized by fluctuating or episodic manifestations of physical discomfort during exertion. These studies primarily focused on adults with coronary artery disease who had a relatively fast resting heart rate (usually ge 70 beats per minute) in normal rhythm. Research examined outcomes related to daily functioning and symptom frequency.

Studies report how symptoms evolved in the observed populations, with findings describing patterns related to changes in the frequency of reported angina attacks and nitrate use. However, when large trials monitored long-term endpoints like cardiovascular death or nonfatal heart attack in the overall broad population, the data did not distinguish outcomes between the Bradia group and the placebo group for these combined endpoints. Subgroup findings, however, indicate patterns associated with fewer recorded events in patients whose heart rate was particularly high at the start of the study.

Evidence for use in Chronic Heart Failure (Reduced Ejection Fraction)

Bradia was evaluated in extensive, multicenter RCTs for patients with symptomatic chronic heart failure involving reduced pumping function (reduced LVEF) and a persistently elevated resting heart rate (ge 70 or ge 75 bpm). Research examined a major composite endpoint that combined measurements of cardiovascular death and hospitalization for worsening heart failure.

Studies report how symptoms evolved, with findings indicating patterns associated with fewer recorded events for the composite primary outcome, largely related to fewer recorded events for hospitalizations due to worsening heart failure. Conversely, when researchers examined cardiovascular death alone, the data were reported as varied, with some major analyses not distinguishing outcomes in this specific measurement.

What is Still Uncertain about Bradia

A key limitation across both the angina and heart failure research is the finding that reported outcomes and observed patterns of change are strongly restricted to patients who already have an elevated resting heart rate at the start of treatment. Data describing outcomes for groups with lower heart rates or those not in sinus rhythm remain sparse. Research has not consistently defined how cardiovascular mortality outcomes are described for the overall populations studied in major outcome trials.

Key Studies & References

1. Ivabradine for treating chronic heart failure (NICE Final appraisal determination)

Common questions about Bradia (FAQ)

Q: Will I feel Bradia working right away?

A: Official product information notes that certain effects, such as a slowed heart rate (bradycardia) and luminous visual phenomena (transient visual changes), are often observed particularly within the first two to three months of treatment. A full assessment of the intended therapeutic effect happens over a longer period as the dose is adjusted.

Q: How long does the effect of Bradia last?

A: Regulatory information that describes how the medicine moves through the body (pharmacokinetics) states that the active ingredient, Ivabradine, has an effective half-life of approximately six hours. The effective half-life measurement supports the regulatory instruction that the medicine should be administered twice daily.

Q: What should I do if I miss a dose of Bradia?

A: Official instructions advise against taking a double dose to make up for a missed dose. Patients are directed to resume their regular routine with the next scheduled dose at the usual time, without taking the missed dose.

Q: Does Bradia make you feel tired or drowsy?

A: While specific symptoms like tiredness or drowsiness are not among the most common adverse reactions listed, official labeling advises patients to report symptoms such as dizziness or fatigue. These may be signs of the known side effect of a very slow heart rate (bradycardia), which is frequently observed.

Q: How long after starting Bradia does the full effect begin?

A: The official administration protocol involves assessing the patient and adjusting the dose based on their resting heart rate after approximately two weeks of treatment. The purpose of this adjustment period is to help align the dose with the intended heart rate target.

Q: What happens if I stop taking Bradia suddenly?

A: Regulatory guidance advises patients not to suddenly stop taking the medicine without first consulting their healthcare provider. The guidance for patients emphasizes the importance of discussing any changes or discontinuation of therapy with their healthcare provider.

Q: What kind of monitoring is needed while taking Bradia?

A: Regulatory guidance specifies that patients should have their heart rhythm monitored regularly. This monitoring checks for the development of an irregular heart rhythm (atrial fibrillation) and symptomatic bradycardia (slow heart rate), along with signs like dizziness or fatigue.

Q: How does Bradia differ from other similar drugs?

A: Bradia belongs to a distinct pharmacological category known as Selective and Specific If Inhibitors. Its unique action is described as slowing the heart rate by selectively blocking the electrical current that sets the heart's natural rhythm. It is distinguished from other drug classes because it does this without broadly affecting the force of the heart muscle's contraction or blood pressure.

Q: Why do doctors prescribe Bradia over other options?

A: Official prescribing information defines a specific patient profile for Bradia's use: individuals with chronic heart conditions who are in normal rhythm and have a persistently elevated resting heart rate (e.g., ge 70 bpm). It is often used when standard treatments, such as beta-blockers, are not well-tolerated or are not sufficient for the patient's needs.

Q: Can Bradia be used for long-term treatment?

A: Bradia is officially indicated for the treatment of chronic stable angina and chronic heart failure. Major clinical studies supporting its indications have followed patients in continued treatment for observation periods extending over one year.

Q: Are there different doses available for Bradia?

A: Yes. Official drug labeling specifies that the active ingredient, Ivabradine, is available as a film-coated tablet in two dosage strengths: 5 mg and 7.5 mg. It is also available as an oral solution.

Q: Do studies support the long-term use of Bradia?

A: Major clinical trials supporting the medicine's indications for chronic conditions provided data from long-term follow-up. These studies, such as the SHIFT and BEAUTIFUL trials, included patients observed for treatment periods extending over 12 months or more.

Q: What is the difference between Bradia and a placebo in studies?

A: In large-scale studies for heart failure, Bradia treatment was associated with a statistically significant finding regarding the primary composite endpoint, largely due to fewer recorded events for hospitalization for worsening heart failure compared to a placebo. This finding was observed in the specified patient population.

Storage Conditions

Bradia (Ivabradine) must be stored at or below 30 C and protected from light and moisture. The tablets must remain in the original blister package to maintain their stability and ensure protection from environmental factors. The medicine should be stored in a secure location and kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Bradia must not be disposed of via wastewater (flushed down the toilet or sink) or routine household waste. The recommended method for disposal is using an authorized pharmaceutical take-back program. If a take-back program is unavailable, follow the official guidance for household disposal, which involves mixing the medicine with an undesirable substance before discarding it.